Curated News
By: NewsRamp Editorial Staff
April 22, 2025
BioVaxys and SpayVac-for-Wildlife Expand Fields of Use in License Agreement
TLDR
- Expansion of SpayVac's markets to include aquaculture enhances revenue potential.
- SpayVac's contraceptive vaccines provide a cost-effective reproductive control solution for farmed fish.
- SpayVac's immunocontraceptive approach offers a humane alternative to genetic manipulation in aquaculture.
- SpayVac's single-dose fertility-control vaccines open new possibilities for sustainable aquaculture and global revenue growth.
Impact - Why it Matters
This news matters as it showcases the innovative expansion of SpayVac's markets into aquaculture, providing a cost-effective solution for reproductive control in farmed fish. The collaboration between BioVaxys and SpayVac-for-Wildlife signifies a significant advancement in the field of biopharmaceuticals and animal health, offering potential benefits for both the companies involved and the global aquaculture sector.
Summary
BioVaxys (CSE: BIOV) (OTCQB:BVAXF) (FRA: 5LB) and SpayVac-for-Wildlife have expanded the fields of use in their license agreement to include commercial aquaculture and the farm-raised fish market. This move significantly increases SpayVac's global revenue potential with its fertility-control vaccines for aquaculture and overabundant feral/wild/invasive animals.
SpayVac-for-Wildlife CEO Thomas D'Orazio highlighted the potential of SpayVac's immunocontraceptive approach as an alternative to genetic manipulation in aquaculture. BioVaxys Technology Corp., a clinical-stage biopharmaceutical company, is dedicated to developing immunotherapies that improve patient lives by utilizing its unique DPX(TM) immune-educating technology platform.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, BioVaxys and SpayVac-for-Wildlife Expand Fields of Use in License Agreement
